TOP HEADLINES

Editor's Corner

Buzz: Ariad soars on reports that Baxalta has come calling about a buyout

Shire has been quiet since making its unwelcomed $30 billion bid to acquire Baxalta public earlier this month. But Baxalta evidently isn't waiting for the next step to play out in that dance. Bloomberg is reporting this afternoon that Baxalta is hunting for an acquisition around the $2 billion mark that would add to its hematology pipeline.

Stem cell researcher cleared of misconduct after U-turn

A stem cell researcher who was accused by colleagues of making up data has been cleared of scientific misconduct. The decision is a boost for Dr. Paolo Macchiarini, a stem cell researcher who went from being featured on the front page of the New York Times to fending off accusations of misconduct.

Intarcia vs. Novo: Which has the most appealing diabetes PhIII program?

Now that Intarcia has come out ahead of Merck's Januvia in the latest study of its implanted extended-release option ITCA-650, some analysts are wondering how the next wrinkle in the big diabetes drug competition will play out.

The FDA offers a controversial solution to the biosimilars name game

The industry has been wrestling for years now over naming the first wave of biosimilars building on the coast of the American drug industry. The FDA's suggested solution: Take the generic name and add four random letters to make it a unique identifier.

Novo Nordisk buys diabetes startups founded by Lilly R&D veteran

Novo Nordisk has gone on a shopping spree in Indiana, picking up a pair of biotechs co-founded by Eli Lilly R&D veteran Richard DiMarchi. The startups, the oldest of which was founded in 2013, are both developing protein-based diabetes drugs based on research performed by DiMarchi.
MORE NEWS

From Our Sister Sites

FierceMedicalDevices

Engineer Scott Leibrand and diabetes patient Dana Lewis have created an artificial pancreas, via years of constant experimentation and iterative upgrades.

FierceMedicalDevices

Insulet said its long-troubled Billerica, MA manufacturing plant is back on track on an earnings call earlier this month--just before the FDA offered details on the OmniPod recalls that were caused by inadequate standards compliance. In July, the company issued a voluntary recall of more than 400,000 OmniPod Insulin Management Systems, which are wearable insulin pumps.